login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
IONIS PHARMACEUTICALS INC (IONS) Stock News
NASDAQ:IONS -
US4622221004
-
Common Stock
61.23
USD
+1.88 (+3.17%)
Last: 9/5/2025, 4:04:04 PM
61.23
USD
0 (0%)
After Hours:
9/5/2025, 4:04:04 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IONS Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Chartmill
- Mentions:
CYTK
UTHR
PPBT
CELU
...
Here are the top movers in Tuesday's session.
3 days ago - By: Chartmill
- Mentions:
CYTK
MNKD
UTHR
SSKN
...
There are notable gap-ups and gap-downs in today's session.
2 days ago - By: Yahoo Finance
Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results
2 days ago - By: Zacks Investment Research
- Mentions:
AZN
GSK
BIIB
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
3 days ago - By: Ionis Pharmaceuticals, Inc.
Ionis to present at upcoming investor conferences
3 days ago - By: Investor's Business Daily
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.
3 days ago - By: Ionis Pharmaceuticals, Inc.
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
6 days ago - By: Chartmill
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup
8 days ago - By: Yahoo Finance
- Mentions:
JPM
J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating
14 days ago - By: Benzinga
Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock
15 days ago - By: Ionis Pharmaceuticals, Inc.
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
a month ago - By: Yahoo Finance
- Mentions:
MS
NVDA
Why Morgan Stanley Upgraded This Biotech Stock to a Buy
a month ago - By: The Motley Fool
Ionis (IONS) Q2 Revenue Soars 101%
a month ago - By: Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
a month ago - By: The Motley Fool
Ionis (IONS) Q2 2025 Earnings Call Transcript
a month ago - By: Ionis Pharmaceuticals, Inc.
Ionis reports second quarter 2025 financial results and highlights progress on key programs
a month ago - By: Ionis Pharmaceuticals, Inc.
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
2 months ago - By: Ionis Pharmaceuticals, Inc.
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
2 months ago - By: Ionis Pharmaceuticals, Inc.
Ionis to hold second quarter 2025 financial results webcast
2 months ago - By: Yahoo Finance
- Mentions:
NKE
RJF
GS
HAS
...
Nike upgraded, Sportradar initiated: Wall Street's top analyst calls
2 months ago - By: Biogen Inc.
- Mentions:
BIIB
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
2 months ago - By: Ionis Pharmaceuticals, Inc.
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Please enable JavaScript to continue using this application.